Mahaprabhu R, Bhandarkar A G, Jangir Babu Lal, Rahangadale S P, Kurkure N V
Department of Pathology, Nagpur Veterinary College, Maharashtra Animal and Fishery Sciences University, Nagpur- 440 006, India.
Toxicol Int. 2011 Jul;18(2):130-6. doi: 10.4103/0971-6580.84265.
An ameliorating effect of Ocimum sanctum on the toxic effect of meloxicam, a new non-steroidal anti-inflammatory drug was studied by evaluating haemato-biochemical parameters, oxidative stress, gross and histopathological changes in various organs of Wistar rats. A total of thirty-six male rats were divided in six experimental groups each comprising of six rats and numbered from G(1) to G(6). Meloxicam toxicity was induced by oral feeding of meloxicam at 1.2 mg/kg and 2.4 mg/kg body weight in G(2) and G(3) respectively for 28 days. Group G(4) and G(5) were fed with 1.2-mg/kg body weight and 2.4-mg/kg body weight of meloxicam along with 200 mg/kg body weight of aqueous extract of Ocimum sanctum. Group G(1) serve as control while group G(6) was kept as treatment control and fed only aqueous extract of Ocimum sanctum at 200 mg/kg body weight. Clinical finding showed mild diarrhea from 23(rd) day onwards in-group treated with 2.4-mg/kg body of meloxicam. Significant reduction of hemoglobin and packed cell volume (PCV) was observed in both the group treated with 1.2 mg/kg and 2.4-mg/kg body wt. of meloxicam. Ocimum sanctum could restore the hemoglobin and PCV value in-group treated with meloxicam at low dose level. Serum alkaline phosphatase, serum glutamic pyruvic transaminase, Serum glutamic oxaloacetic transaminase and total bilirubin were found elevated in meloxicam treated groups and indicated hepatotoxic activity of meloxicam. Ocimum sanctum could reduce hepatotoxic activity of meloxicam in group G4 receiving meloxicam at lower dose rate along with Ocimum sanctum failed to regulate creatinine level in meloxicam treated groups. In meloxicam toxicity elevated Lipid peroxidation values was noticed in liver and kidneys, while superoxide dismutase and glutathione did not revealed any change. Stomach and intestine revealed hemorrhagic gastroenteritis and ulcers. Perivascular necrosis with infiltration with inflammatory cells was evident in liver. Interstitial nephritis, myocardial necrosis and spongiform encephalopathy were important lesions. The Ocimum sanctum could only counteract the toxic effect of meloxicam in liver and gastrointestinal tract.
通过评估Wistar大鼠各器官的血液生化参数、氧化应激、大体和组织病理学变化，研究了圣罗勒对新型非甾体抗炎药美洛昔康毒性作用的改善效果。总共36只雄性大鼠被分为6个实验组，每组6只，从G(1)到G(6)编号。分别在G(2)组和G(3)组中，以1.2毫克/千克和2.4毫克/千克体重的剂量口服美洛昔康28天，诱导美洛昔康毒性。G(4)组和G(5)组分别以1.2毫克/千克体重和2.4毫克/千克体重的美洛昔康与200毫克/千克体重的圣罗勒水提取物一起喂食。G(1)组作为对照组，而G(6)组作为治疗对照组，仅以200毫克/千克体重的剂量喂食圣罗勒水提取物。临床发现显示，在以2.4毫克/千克体重的美洛昔康治疗的组中，从第23天开始出现轻度腹泻。在以1.2毫克/千克和2.4毫克/千克体重的美洛昔康治疗的两组中，均观察到血红蛋白和红细胞压积（PCV）显著降低。圣罗勒可以恢复低剂量美洛昔康治疗组中的血红蛋白和PCV值。在美洛昔康治疗组中，血清碱性磷酸酶、血清谷丙转氨酶、血清谷草转氨酶和总胆红素升高，表明美洛昔康具有肝毒性。圣罗勒可以降低G4组中低剂量美洛昔康与圣罗勒联合治疗时美洛昔康的肝毒性，但未能调节美洛昔康治疗组中的肌酐水平。在美洛昔康毒性作用下，肝脏和肾脏中的脂质过氧化值升高，而超氧化物歧化酶和谷胱甘肽没有任何变化。胃和肠道出现出血性胃肠炎和溃疡。肝脏中可见血管周围坏死伴炎症细胞浸润。间质性肾炎、心肌坏死和海绵状脑病是重要病变。圣罗勒只能抵消美洛昔康在肝脏和胃肠道的毒性作用。
